Using Mass Cytometry to Analyze the Tumor-Infiltrating Lymphocytes in Human Melanoma.


Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2021
Historique:
entrez: 11 3 2021
pubmed: 12 3 2021
medline: 2 4 2021
Statut: ppublish

Résumé

Here we describe the application of mass cytometry to analyze tumor-infiltrating lymphocytes in human melanoma. Mass cytometry is the coupling of flow cytometry and mass spectrometry, which allows for the simultaneous measurement of 40+ cell parameters on a per cell basis. Heavy metal-labeled antibodies can bind to proteins (CD markers, transcription factors, cytokines) on the cell surface and in the cytoplasm/nucleus. As labeled cells pass through the CyTOF, the instrument detects the heavy metals. Combining these signals allows description of melanoma tumor-infiltrating lymphocytes at a greater depth than alternative phenotyping strategies and enables detailed analyses of a variety of cellular parameters, including immune cell lineage, activation status, and functional polarization.

Identifiants

pubmed: 33704739
doi: 10.1007/978-1-0716-1205-7_38
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

543-555

Références

Sumatoh HR, Teng KWW, Cheng Y, Newell EW (2017) Optimization of mass cytometry sample cryopreservation after staining. Cytometry A 91(1):48–61. https://doi.org/10.1002/cyto.a.23014
doi: 10.1002/cyto.a.23014 pubmed: 27798817

Auteurs

Daniela Tantalo (D)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Thu Nguyen (T)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Han Xian Aw Yeang (HXA)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Joe Zhu (J)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Sean Macdonald (S)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Minyu Wang (M)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Harini de Silva (H)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Criselle D'Souza (C)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Angela Pizzolla (A)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Paul J Neeson (PJ)

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. paul.neeson@petermac.org.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia. paul.neeson@petermac.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH